PL359176A1 - Zastosowanie (+)-alfa-(2,3-dimetoksyfenylo)-1-[2-(4-fluorofenylo)etylo]-4-piperydynometanolu lub jego proleku do leczenia objawów otępienia i psychozy wywoływanej przez dopaminę - Google Patents

Zastosowanie (+)-alfa-(2,3-dimetoksyfenylo)-1-[2-(4-fluorofenylo)etylo]-4-piperydynometanolu lub jego proleku do leczenia objawów otępienia i psychozy wywoływanej przez dopaminę

Info

Publication number
PL359176A1
PL359176A1 PL01359176A PL35917601A PL359176A1 PL 359176 A1 PL359176 A1 PL 359176A1 PL 01359176 A PL01359176 A PL 01359176A PL 35917601 A PL35917601 A PL 35917601A PL 359176 A1 PL359176 A1 PL 359176A1
Authority
PL
Poland
Prior art keywords
piperidinemethanol
dimethoxyphenyl
dementia
prodrug
fluorophenyl
Prior art date
Application number
PL01359176A
Other languages
English (en)
Other versions
PL203533B1 (pl
Inventor
Richard Scheyer
Stephen Sorensen
Janice Hitchcock
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of PL359176A1 publication Critical patent/PL359176A1/pl
Publication of PL203533B1 publication Critical patent/PL203533B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
PL359176A 2000-05-25 2001-05-23 Zastosowanie (+)- a-(2,3-dimetoksyfenylo)-1-[2-(4-fluorofenylo)etylo]-4-piperydynometanolu lub jego proleku PL203533B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20694300P 2000-05-25 2000-05-25
US60/206,943 2000-05-25
PCT/US2001/016653 WO2001089498A2 (en) 2000-05-25 2001-05-23 USE OF (+)-α -(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS

Publications (2)

Publication Number Publication Date
PL359176A1 true PL359176A1 (pl) 2004-08-23
PL203533B1 PL203533B1 (pl) 2009-10-30

Family

ID=

Also Published As

Publication number Publication date
DE60133385D1 (de) 2008-05-08
KR100784655B1 (ko) 2007-12-12
DE60133385T2 (de) 2009-04-23
ES2300333T3 (es) 2008-06-16
MXPA02011511A (es) 2003-04-25
PT1289527E (pt) 2008-05-13
NO20025630D0 (no) 2002-11-22
TWI299001B (en) 2008-07-21
US20040204457A1 (en) 2004-10-14
DK1289527T3 (da) 2008-07-14
NZ522659A (en) 2004-06-25
IL152908A0 (en) 2003-06-24
WO2001089498A3 (en) 2002-05-10
CA2410554C (en) 2009-02-03
EP1289527A2 (en) 2003-03-12
EP1289527B1 (en) 2008-03-26
AU6484201A (en) 2001-12-03
US7132433B2 (en) 2006-11-07
US20020099076A1 (en) 2002-07-25
AR029666A1 (es) 2003-07-10
WO2001089498A2 (en) 2001-11-29
KR20030034078A (ko) 2003-05-01
AU2001264842B2 (en) 2005-01-27
CN1436078A (zh) 2003-08-13
NO20025630L (no) 2003-01-24
JP2003535058A (ja) 2003-11-25
BR0111102A (pt) 2003-03-11
ATE390134T1 (de) 2008-04-15
CA2410554A1 (en) 2001-11-29
US20030036553A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
LU91280I2 (fr) Sorafenib et des sels pharmaceutiquement acceptables
HK1062518A1 (en) Materials and methods for the treatment or prevention of obesity
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
SI1572095T1 (sl) Beta-l-2'-deoksinukleozidi za uporabo pri zdravljenju odpornih sevov hbv
HUP0302772A3 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
HUP0301773A3 (en) Apomorphine derivatives and methods for their use
IL152908A0 (en) USE OF (+)-a- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2002314624A1 (en) Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
AU2001265186A1 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
SI1408964T1 (sl) Uporaba 2- 5-(4-fluorofenil)-3-piridilmetil-aminometil -kromana in njegovih fizioloĺ ko sprejemljivih soli
SI1299099T1 (sl) Nova uporaba (r)-(-)-2-5-(4-fluorofenil)-3-piridilmetilaminometil)-kromana in njegovih fiziolosko sprejemljivih soli
PL357106A1 (pl) Nowy sposób wytwarzania -(2,4-disulfofenylo)-N-tert-butylonitronu i jego farmaceutycznie dopuszczalnych soli
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
HK1059782A1 (en) Indole derivatives useful for the treatment of cnsdisorders
GB9802542D0 (en) New use
AU2525201A (en) Combination of cyamemazine and an atypical neuroleptic
HUP0200517A3 (en) Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907
HUP0202145A3 (en) The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
IL135993A0 (en) Pharmaceutical composition for the treatment of fibrosis
PL358267A1 (pl) Kompozycja do zapobiegania i/lub leczenia efektówcytotoksycznych powodowanych stosowaniem środków immunosupresyjnych
IL189557A0 (en) Combination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and therapeutic application thereof
SI1289527T1 (sl) (+)-alfa-(2,3-dimetoksifenil)-1-(2-(4-fluorofenil)etil)-4- piperidinmetanol ali njegova predzdravila za zdravljenje demence ali kognitivne motnje
HU0003973D0 (en) Pharmaceutical composition for the treatment of aids